Equillium (NASDAQ:EQ) Coverage Initiated by Analysts at Oppenheimer

Key Points

• Oppenheimer initiated coverage with an "Outperform" rating and a $7.00 price target — implying roughly a 200% upside from the prior close; the analyst consensus is a "Moderate Buy" with an average target of $7.67.
• Equillium is a small‑cap clinical‑stage biotech (market cap ~$147.33M) with negative earnings (street estimate -$0.22 EPS this year) and notable insider selling recently — the COO sold 120,312 shares and insiders sold 487,468 shares in the past 90 days.

Investment analysts at Oppenheimer started coverage on shares of Equillium (NASDAQ:EQ - Get Free Report) in a note issued to investors on Thursday, Marketbeat.com reports. The brokerage set an "outperform" rating and a $7.00 price target on the stock. Oppenheimer's target price would indicate a potential upside of 200.43% from the company's previous close.

Several other analysts have also recently issued reports on EQ. B. Riley Financial initiated coverage on Equillium in a research note on Thursday, April 16th. They issued a "buy" rating and a $6.00 price objective on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Equillium in a research note on Friday, March 27th. Wall Street Zen upgraded Equillium from a "sell" rating to a "hold" rating in a research note on Saturday, March 14th. Zacks Research upgraded Equillium to a "hold" rating in a research note on Thursday, February 26th. Finally, Roth Mkm reiterated a "buy" rating and issued a $12.00 price objective on shares of Equillium in a research note on Friday, April 17th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $7.67.

Equillium Stock Up 8.4%

NASDAQ:EQ opened at $2.33 on Thursday. The stock's fifty day moving average is $1.93 and its two-hundred day moving average is $1.49. Equillium has a 52 week low of $0.27 and a 52 week high of $2.70. The stock has a market capitalization of $147.33 million, a price-to-earnings ratio of -4.66 and a beta of 1.75.

Equillium (NASDAQ:EQ - Get Free Report) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. On average, sell-side analysts expect that Equillium will post -0.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other Equillium news, COO Christine Zedelmayer sold 120,312 shares of the firm's stock in a transaction on Friday, March 13th. The stock was sold at an average price of $2.50, for a total value of $300,780.00. Following the sale, the chief operating officer directly owned 62,586 shares in the company, valued at $156,465. This trade represents a 65.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 487,468 shares of company stock valued at $990,467 in the last 90 days. 31.60% of the stock is owned by company insiders.

Institutional Trading of Equillium

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC raised its stake in Equillium by 0.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 5,608,078 shares of the company's stock valued at $8,693,000 after buying an additional 48,090 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Equillium in the fourth quarter valued at $9,057,000. Balyasny Asset Management L.P. raised its stake in Equillium by 3.6% in the fourth quarter. Balyasny Asset Management L.P. now owns 2,076,250 shares of the company's stock valued at $3,218,000 after buying an additional 72,602 shares in the last quarter. Cantor Fitzgerald L. P. raised its stake in Equillium by 32.4% in the fourth quarter. Cantor Fitzgerald L. P. now owns 562,643 shares of the company's stock valued at $872,000 after buying an additional 137,643 shares in the last quarter. Finally, Diadema Partners LP raised its stake in Equillium by 15.8% in the fourth quarter. Diadema Partners LP now owns 347,393 shares of the company's stock valued at $538,000 after buying an additional 47,393 shares in the last quarter. 27.05% of the stock is currently owned by institutional investors and hedge funds.

About Equillium

Equillium, Inc NASDAQ: EQ is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.